Genprex wins Nasdaq exception to stay listed, must keep shares above $1 through Dec. 7
GNPX•Reverse split and rule-change note
Genprex implemented a 1-for-22 reverse stock split effective July 16, 2026 to support bid-price compliance.
The filing flagged Nasdaq’s July 22, 2026 rule change enabling immediate suspension for sub-$5 million market value of listed securities for 30 days.
Nasdaq grants Genprex exception on bid-price compliance
Genprex won a Nasdaq hearings panel exception to avoid delisting tied to the $1 minimum bid price rule.
Compliance is required by July 29, 2026; shares must then close at or above $1 each day through Dec. 7, 2026.
The panel kept jurisdiction through Dec. 7, 2026; it can revisit the exception if events undermine continued listing suitability.
